Pacing-Induced CardiomyopathyNCT06100757
Effect of Leadless Pacing on Heart Function
A study testing Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR in people with Pacing-Induced Cardiomyopathy, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
Trial summary
This prospective, un-blinded, randomized, noninferiority, single centre study with 12 month follow-up included patients who were scheduled for a single-chamber PM implant. Patients were 1:1 randomized to undergo the implantation of a conventional VVI pacing system (Medtronic, Advisa ADSR03) with a ventricular pacing… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pacing-Induced Cardiomyopathy
- What is being tested?
- Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 1 siteBelgium
- Study dates
- 1 May 2018to 31 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with a Class I or II indication for single chamber pacemaker following international guidelines
Who cannot join
- patients with previously implanted cardiac devices / mechanical valves that would interfere with the echocardiographic measurements
- patients with inadequate image quality at baseline that prohibited the assessment of myocardial mechanics using echocardiography
- patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline
- patients considered to have a pre-existing condition challenging/precluding the implant of a conventional pacemaker
- patients who refused or were not able to provide written informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Ventricular Mechanical Impact, Contraction Efficiency and Heart Function With Right Ventricular Pacing by MICRATMTPS. Comparison With Conventional RV Pacing
This prospective, un-blinded, randomized, noninferiority, single centre study with 12 month follow-up included patients who were scheduled for a single-chamber PM implant. Patients were 1:1 randomized to undergo the implantation of a conventional VVI pacing system (Medtronic, Advisa ADSR03) with a ventricular pacing lead (Medtronic, 5076-58) in the right ventricle (called 'conventional group') or to be implanted with a leadless Micra TPS (called 'Micra group').
The primary objective was to assess and compare the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.
Read the detailed description
The primary endpoint was to assess the mechanical impact of the Micra TPS on the left ventricular function. The investigators measured the change of Global Longitudinal Strain (GLS) over one year after pacemaker implantation.
As secondary endpoint, the investigators studied the effect of the Micra TPS on the right ventricle using speckle tracking for 2-D myocardial motion estimation. The investigators also assessed conventionally the function of the right ventricle using tricuspid annular plane systolic excursion (TAPSE) in accordance with the guidelines of the European Association of Cardiovascular Imaging and American Society of Echocardiography. Evolution of clinical and biological parameters as NYHA (New York Heart Association) classification, '6 minutes 'walk distance and measurement of brain natriuretic peptide (NT-proBNP) test was also be performed at baseline and after one year follow-up.
Design
It was an interventional prospective not blinded randomized single centre study. The investigators randomized fifty patients into two groups (1:1 ratio) between May 2018 and December 2021:
Group 1 : 25 patients underwent the implantation of a conventional ventricular pacemaker (Medtronic) with placement of a ventricular lead Medtronic 5076-58 in the right ventricle.
Group 2 : 25 patients underwent the implantation of a leadless pacing system Micra TPS.
All implantation procedures were performed under local anaesthesia. To minimize the impact of the pacing site, the investigators targeted as first position the mid septum of the right ventricle. In the presence of inacceptable electrical measurements, an apical positioning was reached. All pacing positions were reviewed according to the Lieberman criteria.
Patients follow-up Patients were followed for a minimal period of 1 year (at 1 month after implantation, 6 months and 12 months as in routine care). Two-dimensional echocardiography was performed 1 day before implantation and at each visit. A 6 minutes' walk distance was performed at day 10 and at 1 year follow-up. As biological marker of the left ventricular function, brain natriuretic peptide (NT-proBNP) was also measured at baseline and at 1 year follow-up.
Device data collections:
The implant procedure duration as the procedure fluoroscopy times were also recorded. Follow-up of the electrical measurements was performed at the same time than the echocardiographic recording.
All complications (implantation failure, device or lead dislodgements, implantation related infection, death) were also prospectively documented.
Conventional 2D-Echocardiography:
Transthoracic echocardiography was performed using a commercially available ultrasound machine (VividTM E95, GE Vingmed Ultrasound AS; Epiq, Philips Medical Systems). Baseline and follow-up echocardiographic examinations were performed using the same machine. Conventional echocardiographic data were analysed according to the recommendations of the European Association of Cardiovascular Imaging. Standard parasternal long- and short-axis and apical four and two-chamber and long axis view were acquired. Left ventricular end-diastolic volume (LVEDV), end-systolic volume (LVESV) and left ventricular ejection fraction were calculated using Simpson's rule in a four-chamber view.
The ystolic function of the right ventricle was evaluated by tricuspid annular plane systolic excursion (TAPSE) in a standard apical four-chamber view. Finally, valve function and particularly tricuspid function was assessed following the European recommendations.
All echocardiographic values will be obtained from the average of measurements from six continuous normal cardiac beats.
Ethical considerations:
The investigators followed the declaration of Helsinki regarding human experimentation. Moreover, the investigators respected national legislation regarding clinical research and confidentiality of the data obtained in this study. All the participants were informed about the aims and procedures of the study and signed an informed consent form before the inclusion in the study. The local ethical committees reviewed and approved this protocol.
- Conditions
- Pacing-Induced Cardiomyopathy
- Being tested
- Micra Transcatheter Pacing System (TPS°, Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR
- Keywords
- leadless pacemaker, Micra Transcatheter pacemaker, ventricular function, valve function
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Micra Transcatheter Pacing System (TPS°Device
Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VRDevice
Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
| Study group | Role | What they receive |
|---|---|---|
| Conventional pacing | Active comparator | 24 patients underwent the implantation of a conventional VVI pacing system (Medtronic) with placement of a ventricular pacing lead Medtronic 5076-58 in the right ventricle. Receives: Device: Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR |
| leadless pacing | Experimental | 27 patients underwent the implantation of a leadless pacing system Micra TPS Receives: Device: Micra Transcatheter Pacing System (TPS° |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment and comparison of the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.
The primary endpoints were the change in left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS)
Measured: 1 year
Secondary outcomes (3)
Evolution of the right ventricular, tricuspid valve and mitral valve function
Echocardiographic measurements at baseline and 1-year follow-up
Measured: 1 year
Evolution of NT-pro-BNP
Measurement of NT-pro BNP at baseline and 1-year follow-up
Measured: 1 year
Evolution of pacemaker performance
Measurement of electrical parameters: pacing threshold, impedance and R-wave sensing. Measurement of percentage of ventricular pacing in both groups.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2023
- Study start1 May 2018
- Primary completion30 Nov 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pacing-Induced CardiomyopathyStudies of the same condition, open and under way.
- More trials run by Universitaire Ziekenhuizen KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- University, hospital or other
- Collaborators
- Medtronic
- Responsible party
- Sponsor
- Investigators
- Christophe Garweg, MD, PhD, Principal investigator, University hospitals of Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06100757
- Sponsor's protocol ID
- S59717
- Status last verified
- Oct 2023
- First submitted
- 20 Oct 2023
- Last updated
- 31 Oct 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Garweg C, Duchenne J, Vandenberk B, Mao Y, Ector J, Haemers P, Poels P, Voigt JU, Willems R. Evolution of ventricular and valve function in patients with right ventricular pacing - A randomized controlled trial comparing leadless and conventional pacing. Pacing Clin Electrophysiol. 2023 Dec;46(12):1455-1464. doi: 10.1111/pace.14870. Epub 2023 Nov 13.
PubMed 37957879
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ventricular Mechanical Impact, Contraction Efficiency and Heart Function With Right Ventricular Pacing by MICRATMTPS. Comparison With Conventional RV Pacing
- ClinicalTrials.gov ID
- NCT06100757
- Acronym / sponsor ID
- S59717
- Conditions
- Pacing-Induced Cardiomyopathy
- Keywords
- leadless pacemaker, Micra Transcatheter pacemaker, ventricular function, valve function
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenUniversity, hospital or other
- Collaborators
- Medtronic
- Study start
- 1 May 2018 (actual)
- Primary completion
- 30 Nov 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 25 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, un-blinded, randomized, noninferiority, single centre study with 12 month follow-up included patients who were scheduled for a single-chamber PM implant. Patients were 1:1 randomized to undergo the implantation of a conventional VVI pacing system (Medtronic, Advisa ADSR03) with a ventricular pacing lead (Medtronic, 5076-58) in the right ventricle (called 'conventional group') or to be implanted with a leadless Micra TPS (called 'Micra group').
The primary objective was to assess and compare the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.
Detailed description
The primary endpoint was to assess the mechanical impact of the Micra TPS on the left ventricular function. The investigators measured the change of Global Longitudinal Strain (GLS) over one year after pacemaker implantation.
As secondary endpoint, the investigators studied the effect of the Micra TPS on the right ventricle using speckle tracking for 2-D myocardial motion estimation. The investigators also assessed conventionally the function of the right ventricle using tricuspid annular plane systolic excursion (TAPSE) in accordance with the guidelines of the European Association of Cardiovascular Imaging and American Society of Echocardiography. Evolution of clinical and biological parameters as NYHA (New York Heart Association) classification, '6 minutes 'walk distance and measurement of brain natriuretic peptide (NT-proBNP) test was also be performed at baseline and after one year follow-up.
Design
It was an interventional prospective not blinded randomized single centre study. The investigators randomized fifty patients into two groups (1:1 ratio) between May 2018 and December 2021:
Group 1 : 25 patients underwent the implantation of a conventional ventricular pacemaker (Medtronic) with placement of a ventricular lead Medtronic 5076-58 in the right ventricle.
Group 2 : 25 patients underwent the implantation of a leadless pacing system Micra TPS.
All implantation procedures were performed under local anaesthesia. To minimize the impact of the pacing site, the investigators targeted as first position the mid septum of the right ventricle. In the presence of inacceptable electrical measurements, an apical positioning was reached. All pacing positions were reviewed according to the Lieberman criteria.
Patients follow-up Patients were followed for a minimal period of 1 year (at 1 month after implantation, 6 months and 12 months as in routine care). Two-dimensional echocardiography was performed 1 day before implantation and at each visit. A 6 minutes' walk distance was performed at day 10 and at 1 year follow-up. As biological marker of the left ventricular function, brain natriuretic peptide (NT-proBNP) was also measured at baseline and at 1 year follow-up.
Device data collections:
The implant procedure duration as the procedure fluoroscopy times were also recorded. Follow-up of the electrical measurements was performed at the same time than the echocardiographic recording.
All complications (implantation failure, device or lead dislodgements, implantation related infection, death) were also prospectively documented.
Conventional 2D-Echocardiography:
Transthoracic echocardiography was performed using a commercially available ultrasound machine (VividTM E95, GE Vingmed Ultrasound AS; Epiq, Philips Medical Systems). Baseline and follow-up echocardiographic examinations were performed using the same machine. Conventional echocardiographic data were analysed according to the recommendations of the European Association of Cardiovascular Imaging. Standard parasternal long- and short-axis and apical four and two-chamber and long axis view were acquired. Left ventricular end-diastolic volume (LVEDV), end-systolic volume (LVESV) and left ventricular ejection fraction were calculated using Simpson's rule in a four-chamber view.
The ystolic function of the right ventricle was evaluated by tricuspid annular plane systolic excursion (TAPSE) in a standard apical four-chamber view. Finally, valve function and particularly tricuspid function was assessed following the European recommendations.
All echocardiographic values will be obtained from the average of measurements from six continuous normal cardiac beats.
Ethical considerations:
The investigators followed the declaration of Helsinki regarding human experimentation. Moreover, the investigators respected national legislation regarding clinical research and confidentiality of the data obtained in this study. All the participants were informed about the aims and procedures of the study and signed an informed consent form before the inclusion in the study. The local ethical committees reviewed and approved this protocol.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional pacing | Active comparator | Device: Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR24 patients underwent the implantation of a conventional VVI pacing system (Medtronic) with placement of a ventricular pacing lead Medtronic 5076-58 in the right ventricle. |
| leadless pacing | Experimental | Device: Micra Transcatheter Pacing System (TPS°27 patients underwent the implantation of a leadless pacing system Micra TPS |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with a Class I or II indication for single chamber pacemaker following international guidelines
Key exclusion criteria (5 listed)
- patients with previously implanted cardiac devices / mechanical valves that would interfere with the echocardiographic measurements
- patients with inadequate image quality at baseline that prohibited the assessment of myocardial mechanics using echocardiography
- patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline
- patients considered to have a pre-existing condition challenging/precluding the implant of a conventional pacemaker
- patients who refused or were not able to provide written informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Micra Transcatheter Pacing System (TPS°Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months | Device | leadless pacing |
| Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VRImplantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months | Device | Conventional pacing |
Primary outcome
Assessment and comparison of the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.
Time frame: 1 year
The primary endpoints were the change in left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS)
3 secondary outcomes
Evolution of the right ventricular, tricuspid valve and mitral valve function
Time frame: 1 year
Evolution of NT-pro-BNP
Time frame: 1 year
Evolution of pacemaker performance
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2023.
- Derived from this study: PubMed 37957879Garweg C, Duchenne J, Vandenberk B, Mao Y, Ector J, Haemers P, Poels P, Voigt JU, Willems R. Evolution of ventricular and valve function in patients with right ventricular pacing - A randomized controlled trial comparing leadless and conventional pacing. Pacing Clin Electrophysiol. 2023 Dec;46(12):1455-1464. doi: 10.1111/pace.14870. Epub 2023 Nov 13.
- Individual participant dataSharing planned: No
Related trials for Pacing-Induced Cardiomyopathy
Active, not recruiting
Physiological Pacing for AV Block to Prevent Pacemaker-induced Cardiomyopathy
Conduction System Pacing, Conventional Ventricular Pacing
RecruitingObservational study
Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation
Atrial Fibrillation (AF), Cardiomyopathy, Secondary
RecruitingObservational study
Pacing Advancements With Cost and Experience VALuation for Unified Patient-Led Clinical Evidence - the PACEVALUE Study
Cardiomyopathy, Secondary, Arrhythmias, Cardiac
Not yet recruiting
Procedural Endpoint in Left Bundle Branch Area Pacing: Conduction System Capture Versus LV Septal Capture
Bradycardia, Atrioventricular Block
RecruitingObservational study
Comparing the Effects of Newer Pacemakers and Their Effects on the Heart and Valve Function in the Short-term.
Pacemaker-Induced Cardiomyopathy, Tricuspid Regurgitation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christophe Garweg, MD, PhD principal investigator
University hospitals of Leuven
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR in people with Pacing-Induced Cardiomyopathy, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment and comparison of the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function. (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06100757, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2023.